Although there are currently no effective therapeutic interventions for keloids, small-molecule inhibitors targeting HMGB1 or its receptors based on silencing HMGB1, RAGE, or TLRs have proven successful in reducing the severity of symptoms in various experimental models of fibrotic diseases [13,14,25,40,41]. This evidence concerns the gene AGER and keloid.